Strong Q3 Results and Buybacks Might Change the Case for Investing in Globus Medical (GMED)

Simply Wall St.11-15

Earlier this month, Globus Medical reported strong third-quarter results with significant increases in sales and net income, raised its full-year 2025 revenue forecast, and confirmed recent share ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2583092633?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163","is_english":true,"pubTime":"2025-11-15 07:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583092633","market":"us","top_or_hot":-1,"title":"Strong Q3 Results and Buybacks Might Change the Case for Investing in Globus Medical (GMED)","media":"Simply Wall St.","content":"<div>\n<p>Earlier this month, Globus Medical reported strong third-quarter results with significant increases in sales and net income, raised its full-year 2025 revenue forecast, and confirmed recent share ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-gmed/globus-medical/news/strong-q3-results-and-buybacks-might-change-the-case-for-inv\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Strong Q3 Results and Buybacks Might Change the Case for Investing in Globus Medical (GMED)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStrong Q3 Results and Buybacks Might Change the Case for Investing in Globus Medical (GMED)\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-15 07:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-gmed/globus-medical/news/strong-q3-results-and-buybacks-might-change-the-case-for-inv><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Earlier this month, Globus Medical reported strong third-quarter results with significant increases in sales and net income, raised its full-year 2025 revenue forecast, and confirmed recent share ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-gmed/globus-medical/news/strong-q3-results-and-buybacks-might-change-the-case-for-inv\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE0009354923.USD","symbol_name":"JANUS HENDERSON US VENTURE \"A2\" (USD) ACC","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-gmed/globus-medical/news/strong-q3-results-and-buybacks-might-change-the-case-for-inv","article_id":"2583092633","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-gmed/globus-medical/news/strong-q3-results-and-buybacks-might-change-the-case-for-inv","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2583092633","pubTimestamp":1763162882,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Earlier this month, Globus Medical reported strong third-quarter results with significant increases in sales and net income, raised its full-year 2025 revenue forecast, and confirmed recent share repurchases under its buyback program.\nAn important insight is that Globus Medical's management emphasized a capital allocation strategy prioritizing innovation, internal investment, and selective acquisitions alongside share buybacks to support long-term value creation for shareholders.\nWe'll...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE0009354923.USD":"JANUS HENDERSON US VENTURE \"A2\" (USD) ACC","BK4082":"医疗保健设备","LU2065732104.USD":"ALLSPRING (LUX) WF GLOBAL SMALL CAP EQUITY \"I\" (USD) ACC","GMED":"Globus Medical Inc"},"translate_title":"强劲的第三季度业绩和回购可能会改变投资Globus Medical(GMED)的理由","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GMED":1.5},"content_text":"Earlier this month, Globus Medical reported strong third-quarter results with significant increases in sales and net income, raised its full-year 2025 revenue forecast, and confirmed recent share repurchases under its buyback program. An important insight is that Globus Medical's management emphasized a capital allocation strategy prioritizing innovation, internal investment, and selective acquisitions alongside share buybacks to support long-term value creation for shareholders. We'll explore how the robust quarterly performance and raised outlook may further reinforce Globus Medical's investment narrative around innovation and market expansion. We've found 16 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.AdvertisementGlobus Medical Investment Narrative Recap To be a Globus Medical shareholder, you have to believe in the company's ability to drive sustained innovation in spine and orthopedics, execute on major acquisitions, and expand internationally, while successfully managing operational risks. The latest quarterly results and raised outlook support the innovation and margin expansion narrative, but do not materially change the fact that integration execution and unpredictable sales cycles in enabling technologies remain the most important near-term catalyst and risk, respectively.\n  The company's announcement of its recent share buyback is directly relevant because it confirms management's ongoing focus on long-term value creation even as integration efforts and international expansion continue. While buybacks can support earnings per share in the short term, the effectiveness will still depend on Globus's ability to absorb acquisitions and maintain revenue momentum in key global markets.\n  However, investors should also be aware of persistent challenges in international markets and how distributor transitions might impact future sales performance...\n Read the full narrative on Globus Medical (it's free!)Globus Medical's narrative projects $3.4 billion revenue and $538.8 million earnings by 2028. This requires 9.0% yearly revenue growth and a $182.2 million increase in earnings from $356.6 million.Uncover how Globus Medical's forecasts yield a $88.80 fair value, a 5% upside to its current price.Exploring Other PerspectivesGMED Community Fair Values as at Nov 2025  Five private investors in the Simply Wall St Community see fair value for Globus Medical anywhere from US$17.32 to US$90. Integration execution risk remains top of mind as you weigh these very different outlooks against current business performance.\nExplore 5 other fair value estimates on Globus Medical - why the stock might be worth less than half the current price!Build Your Own Globus Medical NarrativeDisagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.A great starting point for your Globus Medical research is our analysis highlighting 3 key rewards that could impact your investment decision.Our free Globus Medical research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Globus Medical's overall financial health at a glance.Ready For A Different Approach?Our daily scans reveal stocks with breakout potential. Don't miss this chance:Trump has pledged to \"unleash\" American oil and gas and these 22 US stocks have developments that are poised to benefit.The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.These 13 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2583092633","isCrawlerRequest":true}